Isolated antineutrophil cytoplasmic antibody-associated interstitial lung disease is an increasingly recognized fibrotic ILD phenotype.

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which ...

Morgan Stanley, Leerink Partners, Cantor, and Stifel are acting as joint book-running managers for the offering and Oppenheimer & Co. is acting as lead manager. The offering is subject to market and ...

SAQE, an innovative tool achieving over 90% accuracy in diagnosing Hypersensitivity Pneumonitis, a serious lung condition ...

Upright area-detector CT is equal to or better than supine ADCT in detecting the loss in lung function and assessing the severity of PPF.

Investing.com -- Trevi Therapeutics, Inc. (NASDAQ:TRVI) shares fell 10% in after-hours trading Thursday following the company’s announcement of a proposed public offering of common stock.

Underwriters were given a 30-day option to purchase up to 1.74 million additional shares. ・Trevi is currently developing Haduvio, its treatment for chronic cough in patients with idiopathic pulmonary ...

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva," the "Company" "we" or "us"), a late-stage pharmaceutical company developing therapies ...

Trevi Therapeutics, Inc. TRVI shares are trading higher after the company announced the pricing of its $150 million offering ...

In honor of National Donate Life Month, columnist Sam Kirton shares his story about the impact of receiving a lung transplant ...

BACKGROUND: Genetic variants in components or regulators of the RAS-MAPK signaling pathway are causative for severe and early-onset hypertrophic cardiomyopathy (HCM) in patients with Noonan syndrome ...

Trevi Therapeutics shifts to late-stage biotech with Haduvio for IPF chronic cough. Click here to read my latest analysis of ...